Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD)

Neuromuscular Disorders

Volumn 21, Issue 8, 2011, Pages 569-578

  Nadarajah, V D ^a   van Putten, M ^a   Chaouch, A ^b   Garrood, P ^b   Straub, V ^b   Lochmuller H ^b   Ginjaar, H B ^a   Aartsma Rus, A M ^a   van Ommen, G J B ^a   den Dunnen, J T ^a   't Hoen, P A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Duchenne muscular dystrophy; Matrix metalloproteinase 9; Mdx mouse; Osteopontin; Tissue inhibitors of metalloproteinase 1

Indexed keywords

CORTICOSTEROID; DEFLAZACORT; GELATINASE B; OSTEOPONTIN; PREDNISOLONE; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUADRICEPS FEMORIS MUSCLE; SCHOOL CHILD; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANIMALS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; OSTEOPONTIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960898220     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2011.05.011     Document Type: Article

References (30)

1. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
2. Emery A.E.H., Muntoni F. Confirmation of the Diagnosis, Duchenne Muscular Dystrophy 2003, Oxford, New York, Oxford University Press, pp. 46-75. 3rd ed.
3. Mazzone E.S., Messina S., Vasco G., et al. Reliability of the North star ambulatory assessment in a multicentric setting. Neuromuscul Disord 2009, 19:458-461.
4. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007, 36:424-435.
5. Bushby K., Lochmuller H., Lynn S., Straub V. Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet 2009, 374:1849-1856.
6. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007, 357:2677-2686.
7. Malik V., Rodino-Klapac L.R., Viollet L., et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010, 67:771-780.
8. Li H., Mittal A., Makonchuk D.Y., Bhatnagar S., Kumar A. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet 2009, 18:2584-2598.
9. Pescatori M., Broccolini A., Minetti C., et al. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 2007, 21:1210-1226.
10. Turk R., Sterrenburg E., de Meijer E.J., van Ommen G.J., den Dunnen J.T., t Hoen P.A. Muscle regeneration in dystrophin-deficient mdx mice studied by gene expression profiling. BMC Genomics 2005, 6:98.
11. Vetrone S.A., Montecino-Rodriguez E., Kudryashova E., et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009, 119:1583-1594.
12. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008, 75:346-359.
13. Turk R., Sterrenburg E., van der Wees C.G., et al. Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J 2006, 20:127-129.
14. Pegoraro E., Hoffman E.P., Piva L., et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011, 76:219-226.
15. Haslett J.N., Sanoudou D., Kho A.T., et al. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci USA 2002, 99:15000-15005.
16. De L.A., Nico B., Rolland J.F., et al. Gentamicin treatment in exercised mdx mice: identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis 2008, 32:243-253.
17. Garrood P., Hollingsworth K.G., Eagle M., et al. MR imaging in Duchenne muscular dystrophy: quantification of T1-weighted signal, contrast uptake, and the effects of exercise. J Magn Reson Imaging 2009, 30:1130-1138.
18. Manzur A.Y., Kinali M., Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child 2008, 93:986-990.
19. Castellano G., Malaponte G., Mazzarino M.C., et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008, 14:7470-7480.
20. Sun G.L., Zhao S., Li P., Jiang H.K. Expression of tissue inhibitor of metalloproteinase-1 in progression muscular dystrophy. Neurosci Bull 2006, 22:85-90.
21. Carter G.T., Abresch R.T., Fowler W.M. Adaptations to exercise training and contraction-induced muscle injury in animal models of muscular dystrophy. Am J Phys Med Rehabil 2002, 81:S151-S161.
22. Chen Y.W., Nagaraju K., Bakay M., et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005, 65:826-834.
23. Sun G., Haginoya K., Chiba Y., et al. Elevated plasma levels of tissue inhibitors of metalloproteinase-1 and their overexpression in muscle in human and mouse muscular dystrophy. J Neurol Sci 2010, 297:19-28.
24. De Paiva C.S., Corrales R.M., Villarreal A.L., et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006, 83:526-535.
25. Mysliwiec J., Adamczyk M., Pawlowski P., Nikolajuk A., Gorska M. Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy. Endokrynol Pol 2007, 58:105-109.
26. Goleva E., Hauk P.J., Boguniewicz J., Martin R.J., Leung D.Y. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 2007, 120:1065-1072.
27. Mirowska D., Wicha W., Czlonkowski A., Czlonkowska A., Weber F. Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. J Neuroimmunol 2004, 146:171-175.
28. Wu Z.S., Wu Q., Yang J.H., et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 122:2050-2056.
29. Aartsma-Rus A., van Ommen G.J. Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet 2010, 18:146-153.
30. Brunner S., Kim J.O., Methe H. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am J Cardiol 2010, 105:429-434.